See more : Loblaw Companies Limited (LBLCF) Income Statement Analysis – Financial Results
Complete financial analysis of DIAGNOS Inc. (DGNOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DIAGNOS Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Ribo Fashion Group Co., Ltd. (603196.SS) Income Statement Analysis – Financial Results
- Sansei Landic Co.,Ltd (3277.T) Income Statement Analysis – Financial Results
- Jianglong Shipbuilding Co., Ltd. (300589.SZ) Income Statement Analysis – Financial Results
- Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Income Statement Analysis – Financial Results
- China Molybdenum Co., Ltd. (603993.SS) Income Statement Analysis – Financial Results
DIAGNOS Inc. (DGNOF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.diagnos.ca
About DIAGNOS Inc.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K | 326.47K | 1.61M | 2.39M | 981.48K | 564.18K | 2.70M | 1.51M | 1.33M | 1.07M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Cost of Revenue | 1.01M | 857.13K | 614.60K | 804.97K | 1.09M | 1.09M | 1.32M | 1.67M | 1.18M | 1.11M | 2.24M | 1.02M | 104.54K | 24.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -837.94K | -418.30K | -347.53K | -473.46K | -759.37K | -759.37K | 290.90K | 719.10K | -203.51K | -541.43K | 464.53K | 490.00K | 1.22M | 1.05M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Gross Profit Ratio | -492.45% | -95.32% | -130.13% | -142.81% | -232.60% | -232.60% | 18.04% | 30.09% | -20.73% | -95.97% | 17.17% | 32.47% | 92.13% | 97.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 1.08M | 603.35K | 0.00 | 0.00 | 0.00 | 922.49K | 0.00 | 1.18M | 1.07M | 1.31M | 1.00M | 831.56K | 793.96K | 614.13K | 618.21K | 674.24K | 193.82K | 101.25K | 179.58K | 784.10K | -4.56K | 192.92K | 1.44M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.84M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -293.72K | -295.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.77M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 2.46M | 2.10M | 1.69M | 3.23M | 2.02M | 1.39M | 1.09M | 1.10M | 426.23K | 567.04K | 1.45M |
| Other Expenses | 0.00 | 100.14K | 264.28K | 85.80K | 52.31K | 52.31K | 0.00 | 0.00 | 1.07M | 0.00 | 0.00 | -374.80K | -240.63K | -204.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.76M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 3.15M | 2.66M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Cost & Expenses | 3.86M | 3.10M | 2.55M | 3.13M | 3.26M | 3.26M | 4.08M | 4.36M | 3.70M | 3.23M | 4.35M | 3.56M | 3.25M | 2.69M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Interest Income | 6.89K | 5.38K | 5.38K | 3.23K | 3.23K | 1.48K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23K | 11.89K | 27.01K | 8.79K | 15.44K | 76.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 550.17K | 53.78K | 32.16K | 347.11K | 1.03M | 1.03M | 827.77K | 955.38K | 469.22K | 159.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.25K | 0.00 | 0.00 |
| Depreciation & Amortization | 124.21K | 101.17K | 105.80K | 92.84K | 101.72K | 191.32K | 230.19K | 192.65K | 82.37K | 43.71K | 62.19K | 89.52K | 81.36K | 125.94K | 186.17K | 188.36K | 79.67K | 32.68K | 29.28K | 23.66K | 75.05K | 139.36K | 176.19K |
| EBITDA | -2.45M | -2.10M | -2.45M | -2.61M | -2.69M | -2.69M | -2.66M | -1.78M | -2.64M | -2.62M | -1.58M | -1.97M | -1.84M | -1.49M | -1.74M | -1.97M | -347.40K | -711.98K | -560.21K | -1.77M | -33.96K | -631.34K | -2.88M |
| EBITDA Ratio | -1,437.61% | -557.99% | -723.29% | -785.96% | -822.85% | -822.39% | -164.64% | -74.54% | -269.07% | -465.19% | -58.55% | -130.30% | -134.65% | -184.81% | -485.96% | -104.35% | -18.65% | -91.78% | -78.99% | -1,587.96% | -8.76% | -490.86% | -41,123.96% |
| Operating Income | -3.69M | -2.55M | -2.02M | -2.71M | -2.88M | -2.88M | -2.89M | -1.97M | -2.72M | -2.67M | -1.65M | -2.06M | -2.22M | -1.58M | -1.93M | -2.16M | -427.07K | -744.66K | -589.49K | -1.80M | -109.01K | -770.70K | -3.05M |
| Operating Income Ratio | -2,168.30% | -582.10% | -756.03% | -816.65% | -881.45% | -881.00% | -178.91% | -82.60% | -277.46% | -472.94% | -60.85% | -136.23% | -167.19% | -147.33% | -537.96% | -114.34% | -22.92% | -96.00% | -83.12% | -1,609.13% | -28.12% | -599.21% | -43,640.96% |
| Total Other Income/Expenses | 568.95K | -259.14K | 608.66K | 232.12K | -505.21K | -1.03M | -622.77K | 232.83K | 475.50K | -159.40K | 5.23K | 11.89K | 27.01K | 275.63K | 0.00 | 0.00 | 0.00 | 124.41K | 8.37K | 64.85K | 26.20K | -57.70K | -123.17K |
| Income Before Tax | -3.12M | -2.61M | -2.05M | -3.38M | -3.90M | -3.90M | -3.09M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | 0.00 | 0.00 | 0.00 | -620.25K | -581.12K | -1.73M | -82.81K | -828.40K | -3.18M |
| Income Before Tax Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,195.74% | -1,195.74% | -191.55% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | 0.00% | 0.00% | 0.00% | -79.96% | -81.94% | -1,551.10% | -21.36% | -644.07% | -45,400.57% |
| Income Tax Expense | 0.00 | 153.92K | 296.44K | 432.91K | -64.67K | -64.67K | -192.19K | -1.32M | 0.00 | 0.00 | 0.00 | -540.22K | 28.02K | -508.81K | -15.44K | -76.43K | -28.99K | -3.12K | 747.00 | 12.79K | 47.25K | -33.48K | 4.58K |
| Net Income | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M | -3.84M | -2.90M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | -1.91M | -2.08M | -398.09K | -617.13K | -581.86K | -1.75M | -130.06K | -762.98K | -3.18M |
| Net Income Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,175.93% | -1,175.93% | -179.63% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | -533.64% | -110.28% | -21.37% | -79.56% | -82.05% | -1,562.55% | -33.54% | -593.21% | -45,465.96% |
| EPS | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| Weighted Avg Shares Out | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
| Weighted Avg Shares Out (Dil) | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
DIAGNOS to be Featured on CEO Clips on the BNN Bloomberg Channel
BROSSARD, Quebec, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of certain critical health issues, announces it will be featured on CEO Clips on...
DIAGNOS Announces a Multi-Year Contract with Juarez Health & Medical Tourism Cluster
BROSSARD, Quebec, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of certain critical health issues, announces the signing of a 7-year contract with Juarez...
DIAGNOS Announces Voting Results of Annual Meeting of Shareholders
BROSSARD, Quebec, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces...
DIAGNOS Announces a Three-Year Contract Renewal with Optina Diagnostics Providing a Telemedicine Platform to Support their Early Detection of Alzheimer's Disease Test
BROSSARD, Quebec, Sept. 02, 2021 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of certain critical health issues, announces today a contract renewal to provide its telemedicine...
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
BROSSARD, Quebec, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues, announces that the 2021 annual general and special meeting of shareholders (the “Meeting”)...
DIAGNOS Announces the Official Opening of the AI Assisted Screening Clinic at Magrabi Hospital with the Presence of the Undersecretary of the Ministry of Health of Saudi Arabia
BROSSARD, Quebec, July 22, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce the official opening of the initial...
DIAGNOS initiates a clinical trial study in the USA for early detection and prevention of Stroke using its new application CARA-STROKE
BROSSARD, Quebec, July 20, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the initiation of a clinical trial study with CommonSpirit Health...
DIAGNOS Announces a Pilot with Hospital Oftalmológico Buena Vista Sinaloa
BROSSARD, Quebec, June 15, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the signing of a 2-month pilot with Hospital Oftalmológico Buena...
DIAGNOS Enters into an Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People
BROSSARD, Quebec, April 06, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial...
DIAGNOS and the third largest optical retailer in Costa Rica Piloting CARA and its Telemedicine technology
BROSSARD, Quebec, March 04, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
Source: https://incomestatements.info
Category: Stock Reports